https://hfsa.digitellinc.com/p/cf/2016-hfsa-board-review-advanced-heart-failure-and-transplant-cardiology-ondemand-2
https://hfsa.digitellinc.com/p/s/live-abim-style-question-session-3
https://hfsa.digitellinc.com/p/s/heart-failure-epidemiology-and-risk-factors-5
https://hfsa.digitellinc.com/p/s/pathophysiology-i-cellular-and-energetic-considerations-and-pathophysiology-ii-hemodynamic-structural-and-neurohormonal-considerations-6
https://hfsa.digitellinc.com/p/s/clinical-assessment-i-diagnosis-co-morbidities-8
https://hfsa.digitellinc.com/p/s/working-lunch-contemporary-topics-arnis-and-ivabradine-9
https://hfsa.digitellinc.com/p/s/clinical-assessment-ii-functional-capacity-prognosis-10
https://hfsa.digitellinc.com/p/s/hemodynamics-in-heart-failure-i-11
https://hfsa.digitellinc.com/p/s/hemodynamics-in-heart-failure-ii-12
https://hfsa.digitellinc.com/p/s/cardiomyopathies-i-ischemic-and-valvular-13
https://hfsa.digitellinc.com/p/s/cardiomyopathies-ii-nonischemic-and-peripartum-14
https://hfsa.digitellinc.com/p/s/cardiomyopathies-iii-hcm-and-inherited-15
https://hfsa.digitellinc.com/p/s/cardiomyopathies-iv-arvd-and-sarcoid-16
https://hfsa.digitellinc.com/p/s/faculty-available-for-q-and-a-17
https://hfsa.digitellinc.com/p/s/introduction-to-the-day-and-live-abim-style-question-session-30-min-20
https://hfsa.digitellinc.com/p/s/cardio-oncology-21
https://hfsa.digitellinc.com/p/s/heart-transplantation-overview-and-patient-selection-22
https://hfsa.digitellinc.com/p/s/immunology-the-basics-pra-sensitization-crossmatch-23
https://hfsa.digitellinc.com/p/s/rejection-cellular-and-antibody-mediated-24
https://hfsa.digitellinc.com/p/s/managing-immunosuppression-and-drugs-25
https://hfsa.digitellinc.com/p/s/post-transplant-management-issues-26
https://hfsa.digitellinc.com/p/s/mcs-i-cardiogenic-shock-and-temporary-support-devices-27
https://hfsa.digitellinc.com/p/s/working-lunch-contemporary-topics-ambulatory-hemodynamic-monitoring-28
https://hfsa.digitellinc.com/p/s/mcs-ii-durable-mcs-selection-and-outcomes-29
https://hfsa.digitellinc.com/p/s/mcs-iii-adverse-events-and-patient-management-30
https://hfsa.digitellinc.com/p/s/pulmonary-hypertension-31
https://hfsa.digitellinc.com/p/s/pericarditis-and-myocarditis-32
https://hfsa.digitellinc.com/p/s/hfpef-and-infiltrative-cardiomyopathies-33
https://hfsa.digitellinc.com/p/s/disease-management-and-palliative-care-34
https://hfsa.digitellinc.com/p/s/biomarkers-in-heart-failure-35
https://hfsa.digitellinc.com/p/s/landmark-heart-failure-trails-36
https://hfsa.digitellinc.com/p/s/introduction-to-the-day-and-q-and-a-39
https://hfsa.digitellinc.com/p/s/drug-therapy-for-chronic-heart-failure-i-40
https://hfsa.digitellinc.com/p/s/drug-therapy-for-chronic-heart-failure-ii-41
https://hfsa.digitellinc.com/p/s/acute-decompensated-heart-failure-i-42
https://hfsa.digitellinc.com/p/s/acute-decompensated-heart-failure-ii-43
https://hfsa.digitellinc.com/p/s/management-of-arrhythmias-in-heart-failure-44
https://hfsa.digitellinc.com/p/s/device-therapy-in-heart-failure-45
https://hfsa.digitellinc.com/packages/3/view
https://hfsa.digitellinc.com/p/s/clinical-fundamentals-the-hemodynamics-of-hf-59
https://hfsa.digitellinc.com/p/s/new-horizons-in-nutrition-in-hf-62
https://hfsa.digitellinc.com/p/s/transitioning-patients-out-of-the-hospital-and-keeping-them-out-joint-session-with-aahfn-63
https://hfsa.digitellinc.com/p/s/navigating-the-slippery-slope-of-advanced-hfs-a-look-beyond-the-usual-suspects-64
https://hfsa.digitellinc.com/p/s/the-prevention-of-hf-joint-session-with-aha-66
https://hfsa.digitellinc.com/p/s/the-systemic-effects-of-continuous-flow-physiology-67
https://hfsa.digitellinc.com/p/s/diagnostic-biomarkers-and-imaging-for-myocarditis-and-non-ischemic-cardiomyopathies-joint-session-with-myocarditis-foundation-68
https://hfsa.digitellinc.com/p/s/excellence-in-translational-research-hf-a-systematic-storm-organ-to-organ-cross-talk-from-pathophysiology-to-innovative-therapeutics-69
https://hfsa.digitellinc.com/p/s/interpreting-therapeutic-advancements-and-addressing-clinical-challenges-in-heart-failure-management-71
https://hfsa.digitellinc.com/p/s/cardiac-amyloidosis-a-multidisciplinary-approach-to-understanding-diagnosis-and-treatment-72
https://hfsa.digitellinc.com/p/s/pulmonary-artery-pressure-guided-therapy-for-heart-failure-patients-rationale-and-challenges-73
https://hfsa.digitellinc.com/p/s/the-perfect-storm-of-heart-failure-and-diabetes-insights-into-pathophysiology-and-evidence-based-treatment-strategies-74
https://hfsa.digitellinc.com/p/s/opening-remarks-awards-and-presidents-address-76
https://hfsa.digitellinc.com/p/s/plenary-human-ips-cells-from-precision-medicine-to-clinical-trial-in-a-dish-77
https://hfsa.digitellinc.com/p/s/think-venous-venous-congestion-as-a-key-determinant-of-pathophysiology-and-outcomes-in-hf-78
https://hfsa.digitellinc.com/p/s/management-of-hfpef-in-2016-surviving-in-a-data-free-world-79
https://hfsa.digitellinc.com/p/s/heart-failure-trials-late-breaking-updates-80
https://hfsa.digitellinc.com/p/s/cutting-edge-concepts-in-device-therapy-for-hf-joint-session-with-hrs-81
https://hfsa.digitellinc.com/p/s/genetics-and-cardiomyopathies-82
https://hfsa.digitellinc.com/p/s/echocardiogram-made-simple-for-the-multidisciplinary-team-84
https://hfsa.digitellinc.com/p/s/how-to-integrating-nutrition-into-hf-management-85
https://hfsa.digitellinc.com/p/s/how-to-using-technologies-for-self-management-in-patients-with-hf-86
https://hfsa.digitellinc.com/p/s/how-to-manage-hf-in-a-multiple-comorbid-condition-world-its-complicated-87
https://hfsa.digitellinc.com/p/s/how-to-decision-support-for-patients-with-hf-facing-tough-options-88
https://hfsa.digitellinc.com/p/s/rapid-fire-abstracts-i-89
https://hfsa.digitellinc.com/p/s/guideline-session-a-global-view-joint-session-with-hfa-of-esc-and-jhfs-90
https://hfsa.digitellinc.com/p/s/controversies-in-cardiac-amyloidosisinfiltrative-cardiomyopathies-91
https://hfsa.digitellinc.com/p/s/fda-special-session-off-label-drug-use-92
https://hfsa.digitellinc.com/p/s/my-patients-do-what-i-tell-them-dont-they-93
https://hfsa.digitellinc.com/p/s/simplifying-hemodynamics-with-complex-pressure-volume-loops-94
https://hfsa.digitellinc.com/p/s/late-breaking-clinical-trials-95
https://hfsa.digitellinc.com/p/s/controversies-in-mechanical-circulatory-support-96
https://hfsa.digitellinc.com/p/s/primary-palliative-care-in-hf-what-can-you-do-97
https://hfsa.digitellinc.com/p/s/hyperkalemia-implication-for-hf-management-98
https://hfsa.digitellinc.com/p/s/to-dc-or-not-to-dc-managing-hyperkalemia-in-the-hf-patient-on-an-acearb-andor-mra-optimizing-patient-benefits-and-risks-99
https://hfsa.digitellinc.com/p/s/clinical-fundamentals-ii-discharging-patients-after-ahf-admission-101
https://hfsa.digitellinc.com/p/s/case-discussion-clinical-conundrums-102
https://hfsa.digitellinc.com/p/s/unraveling-the-non-invasive-cardiac-phenome-for-hf-precision-medicine-103
https://hfsa.digitellinc.com/p/s/jnc-young-investigators-award-clinicalintegrative-104
https://hfsa.digitellinc.com/p/s/nursing-research-award-105
https://hfsa.digitellinc.com/p/s/jnc-young-investigators-award-basic-science-106
https://hfsa.digitellinc.com/p/s/meet-the-experts-q-and-a-with-hf-editors-107
https://hfsa.digitellinc.com/p/s/updates-in-hf-pharmacology-108
https://hfsa.digitellinc.com/p/s/neprilysin-inhibitors-clinically-available-now-what-109
https://hfsa.digitellinc.com/p/s/symptom-perception-in-hf-110
https://hfsa.digitellinc.com/p/s/how-to-partner-with-industry-to-advance-scientific-knowledge-in-hf-111
https://hfsa.digitellinc.com/p/s/cardiopulmonary-function-testing-112
https://hfsa.digitellinc.com/p/s/how-to-have-tough-discussions-with-patients-and-families-critical-conversations-113
https://hfsa.digitellinc.com/p/s/how-to-home-hemodynamic-monitoring-for-hf-patients-114
https://hfsa.digitellinc.com/p/s/how-to-transitioning-support-within-a-spectrum-of-collaboration-115
https://hfsa.digitellinc.com/p/s/how-to-destination-therapy-vad-program-logistics-development-and-economics-116
https://hfsa.digitellinc.com/p/s/rapid-fire-abstracts-ii-118
https://hfsa.digitellinc.com/p/s/pulmonary-hypertension-in-patients-with-hf-119
https://hfsa.digitellinc.com/p/s/hyde-park-120
https://hfsa.digitellinc.com/p/s/new-developments-in-cardio-oncology-121
https://hfsa.digitellinc.com/p/s/hf-in-achd-optimizing-therapies-for-an-evolving-problem-122
https://hfsa.digitellinc.com/p/s/individualizing-the-assessment-of-patients-with-hf-steps-towards-precision-care-124
https://hfsa.digitellinc.com/p/s/case-based-debate-125
https://hfsa.digitellinc.com/p/s/application-of-big-data-in-hf-the-sky-is-the-limit-126
https://hfsa.digitellinc.com/p/s/caregiver-support-what-can-caregivers-deliver-what-are-the-outcomes-for-patients-and-caregivers-127
https://hfsa.digitellinc.com/p/s/clinical-fundamentals-iii-cognitive-deficits-in-hf-chicken-or-the-egg-129
https://hfsa.digitellinc.com/p/s/preventing-and-treating-rejection-primer-for-the-cardiac-transplant-physician-130
https://hfsa.digitellinc.com/p/s/hf-with-recovered-ejection-fraction-131
https://hfsa.digitellinc.com/p/s/new-therapeutic-targets-in-hfpef-132
https://hfsa.digitellinc.com/p/s/implementing-novel-therapies-to-improve-outcomes-for-our-patients-133
https://hfsa.digitellinc.com/p/s/matching-the-market-share-in-hf-women-versus-men-134
https://hfsa.digitellinc.com/p/s/embracing-complexity-managing-frailty-and-multi-morbidity-in-older-hf-patients-135
https://hfsa.digitellinc.com/p/s/nonpharmacologic-and-behavioral-approaches-to-reducing-symptom-distress-in-advanced-hf-136
https://hfsa.digitellinc.com/p/s/in-hospital-worsening-hf-what-is-it-137
https://hfsa.digitellinc.com/p/s/coronary-artery-diseases-in-patients-with-hf-138
https://hfsa.digitellinc.com/packages/4/view
https://hfsa.digitellinc.com/p/s/the-er-as-a-safety-net-for-ahf-patients-joint-session-with-saem-140
https://hfsa.digitellinc.com/p/s/synchronized-care-strategies-to-improve-patient-and-healthcare-outcomes-in-heart-failure-141
https://hfsa.digitellinc.com/p/s/clinical-fundamentals-i-the-immune-response-in-cardiovascular-disease-145
https://hfsa.digitellinc.com/p/s/transitions-in-heart-failure-care-its-not-just-about-hospital-to-home-146
https://hfsa.digitellinc.com/p/s/hemodynamics-in-heart-failure-joint-session-with-scai-147
https://hfsa.digitellinc.com/p/s/ask-the-experts-challenging-clinical-situations-in-mcs-148
https://hfsa.digitellinc.com/p/s/recent-advances-in-the-management-of-myocarditis-joint-session-149
https://hfsa.digitellinc.com/p/s/the-prevention-of-heart-failure-targets-and-strategies-joint-session-aha-150
https://hfsa.digitellinc.com/p/s/tool-kit-for-the-evaluation-and-selection-of-the-patient-for-mcs-iccac-vad-joint-session-151
https://hfsa.digitellinc.com/p/s/excellence-in-translational-science-bench-to-bedside-152
https://hfsa.digitellinc.com/p/s/disposition-decision-making-from-the-er-joint-session-saem-153
https://hfsa.digitellinc.com/p/s/plenary-154
https://hfsa.digitellinc.com/p/s/heart-failure-trials-the-year-in-review-155
https://hfsa.digitellinc.com/p/s/cutting-edge-concepts-in-device-therapy-for-heart-failure-joint-session-with-hrs-156
https://hfsa.digitellinc.com/p/s/what-is-the-best-way-to-measure-congestion-in-the-patient-with-heart-failure-157
https://hfsa.digitellinc.com/p/s/new-concepts-in-the-pathophysiology-of-hfpef-158
https://hfsa.digitellinc.com/p/s/born-this-way-the-role-of-genetic-testing-in-cardiomyopathy-159
https://hfsa.digitellinc.com/p/s/how-to-change-behavior-160
https://hfsa.digitellinc.com/p/s/how-to-troubleshoot-a-vad-161
https://hfsa.digitellinc.com/p/s/rapid-fire-abstracts-i-162
https://hfsa.digitellinc.com/p/s/how-to-cases-in-the-evaluation-and-management-of-right-heart-failure-in-the-patient-with-pulmonary-arterial-hypertension-163
https://hfsa.digitellinc.com/p/s/how-to-opportunities-in-early-career-nursing-164
https://hfsa.digitellinc.com/p/s/nhlbi-special-session-heart-failure-clinical-trails-strategies-to-optimize-enrollment-165
https://hfsa.digitellinc.com/p/s/guideline-session-unique-heart-failure-populations-what-makes-them-166
https://hfsa.digitellinc.com/p/s/cardiac-amyloidosis-167
https://hfsa.digitellinc.com/p/s/from-tele-monitoring-to-tele-management-and-electronic-and-mobile-health-in-heart-failure-168
https://hfsa.digitellinc.com/p/s/late-breaking-clinical-trials-169
https://hfsa.digitellinc.com/p/s/moving-from-the-problem-to-the-solution-integrating-a-palliative-approach-in-heart-failure-management-170
https://hfsa.digitellinc.com/p/s/managing-vad-complications-171
https://hfsa.digitellinc.com/p/s/from-bench-to-bedside-emerging-therapies-for-the-failing-myocardium-172
https://hfsa.digitellinc.com/p/s/clinical-fundamentals-ii-faqs-about-drug-therapy-173
https://hfsa.digitellinc.com/p/s/cardiovascular-magnetic-resonance-imaging-for-the-heart-failure-specialist-174
https://hfsa.digitellinc.com/p/s/case-discussion-clinical-conundrums-175
https://hfsa.digitellinc.com/p/s/nursing-research-award-176
https://hfsa.digitellinc.com/p/s/jnc-young-investigators-award-basic-science-177
https://hfsa.digitellinc.com/p/s/jnc-young-investigators-award-clinicalintegrative-178
https://hfsa.digitellinc.com/p/s/managing-the-vad-outpatient-179
https://hfsa.digitellinc.com/p/s/putting-the-self-back-in-self-care-joint-session-with-aahfn-180
https://hfsa.digitellinc.com/p/s/controversies-in-cardio-oncology-181
https://hfsa.digitellinc.com/p/s/the-hidden-gems-of-heart-failure-publishing-182
https://hfsa.digitellinc.com/p/s/how-to-use-cardiac-rehabilitation-in-heart-failure-183
https://hfsa.digitellinc.com/p/s/rapid-fire-abstracts-ii-184
https://hfsa.digitellinc.com/p/s/how-to-manage-diuretic-resistance-what-to-do-when-the-fluid-wont-come-off-185
https://hfsa.digitellinc.com/p/s/how-to-conduct-bedside-assessment-in-heart-failure-186
https://hfsa.digitellinc.com/p/s/how-to-manage-sleep-apnea-in-heart-failure-187
https://hfsa.digitellinc.com/p/s/hyde-park-session-188
https://hfsa.digitellinc.com/p/s/interventional-structural-devices-for-heart-failure-189
https://hfsa.digitellinc.com/p/s/load-unloading-remodeling-and-recovery-190
https://hfsa.digitellinc.com/p/s/whats-new-and-emerging-in-heart-failure-pharmacology-191
https://hfsa.digitellinc.com/p/s/alternative-therapies-for-heart-failure-fact-or-fiction-192
https://hfsa.digitellinc.com/p/s/emergency-management-of-vad-patients-joint-ishlt-193
https://hfsa.digitellinc.com/p/s/how-to-interpret-biomarker-studies-194
https://hfsa.digitellinc.com/p/s/managing-the-patient-with-newly-diagnosed-heart-failure-195
https://hfsa.digitellinc.com/p/s/clinical-fundamentals-iii-acute-heart-failure-360-196
https://hfsa.digitellinc.com/p/s/the-periphery-in-heart-failure-more-than-an-innocent-bystander-197
https://hfsa.digitellinc.com/p/s/right-sided-heart-failure-what-do-we-do-when-orthopnea-is-traded-for-ascites-198
https://hfsa.digitellinc.com/p/s/heart-failure-clinics-the-evidence-the-need-and-the-redesign-199
https://hfsa.digitellinc.com/p/s/interventions-for-vulnerable-patients-200
https://hfsa.digitellinc.com/p/s/update-on-peripartum-cardiomyopathy-and-pregnancy-associated-heart-failure-201
https://hfsa.digitellinc.com/p/s/pharmacogenetics-of-heart-failure-and-transplant-additive-or-redundant-202
https://hfsa.digitellinc.com/p/s/international-session-new-clinical-insights-into-hfpef-joint-session-with-hfa-and-japanese-hf-society-203
https://hfsa.digitellinc.com/packages/6/view
https://hfsa.digitellinc.com/packages/7/view
https://hfsa.digitellinc.com/packages/8/view
https://hfsa.digitellinc.com/packages/9/view
https://hfsa.digitellinc.com/packages/10/view
https://hfsa.digitellinc.com/p/cf/satellite-symposium-synchronized-care-259
https://hfsa.digitellinc.com/p/cf/satellite-symposium-to-dc-or-not-to-dc-261
https://hfsa.digitellinc.com/packages/13/view
https://hfsa.digitellinc.com/p/cf/satellite-symposium-cardiac-amyloidosis-265
https://hfsa.digitellinc.com/p/cf/satellite-symposium-pulmonary-artery-268
https://hfsa.digitellinc.com/p/cf/satellite-symposium-heart-failure-and-diabetes-269
https://hfsa.digitellinc.com/p/cf/satellite-symposium-interpreting-therapeutic-advancements-272
https://hfsa.digitellinc.com/p/cf/hfsas-21st-annual-scientific-meeting-289
https://hfsa.digitellinc.com/p/s/heart-failure-diagnostic-testing-and-advanced-therapies-304
https://hfsa.digitellinc.com/p/s/heart-failure-moods-in-hf-and-caregiver-challenges-314
https://hfsa.digitellinc.com/p/s/heart-failure-medications-and-challenges-of-multiple-medications-325
https://hfsa.digitellinc.com/p/s/hfpef-current-and-emerging-approaches-to-diagnosis-and-evaluation-of-hfpef-329
https://hfsa.digitellinc.com/p/s/call-the-shock-team-332
https://hfsa.digitellinc.com/p/s/joint-session-hrs-contemporary-ep-issues-in-hf-335
https://hfsa.digitellinc.com/p/s/joint-session-myocarditis-foundation-the-elephant-in-the-rheum-the-autoimmune-cardiomyopathies-338
https://hfsa.digitellinc.com/p/s/excellence-in-translational-science-emerging-inotrope-strategies-bench-to-bedside-341
https://hfsa.digitellinc.com/p/s/joint-session-aha-what-can-you-do-to-prevent-hf-344
https://hfsa.digitellinc.com/p/s/joint-session-aahfn-heart-failure-readmissions-is-there-anything-new-347
https://hfsa.digitellinc.com/p/s/joint-session-scmr-350
https://hfsa.digitellinc.com/p/s/opening-remarks-history-of-hfsa-video-awards-and-presidents-address-353
https://hfsa.digitellinc.com/p/s/plenary-session-heart-failure-care-in-america-a-public-patient-and-provider-perspective-356
https://hfsa.digitellinc.com/p/s/the-cardiac-interstitial-space-in-health-and-disease-the-final-frontier-359
https://hfsa.digitellinc.com/p/s/the-hospitalized-patient-with-hf-362
https://hfsa.digitellinc.com/p/s/hope-for-hfpef-on-the-horizon-pharmacotherapies-in-development-for-hfpef-365
https://hfsa.digitellinc.com/p/s/diagnosing-and-treating-cardiorenal-syndrome-in-heart-failure-from-bench-to-bedside-and-beyond-368
https://hfsa.digitellinc.com/p/s/managing-diabetes-and-hf-371
https://hfsa.digitellinc.com/p/s/myocardial-recovery-following-mechanically-assisted-circulation-hype-or-promise-374
https://hfsa.digitellinc.com/p/s/how-to-manage-valvular-heart-disease-in-hf-377
https://hfsa.digitellinc.com/p/s/know-when-to-holdem-drugs-to-avoid-or-use-cautiously-in-heart-failure-380
https://hfsa.digitellinc.com/p/s/rapid-fire-abstracts-i-383
https://hfsa.digitellinc.com/p/s/joint-session-esc-hfa-and-jhfs-and-chfs-heart-failure-world-wide-challenges-opportunities-and-barriers-386
https://hfsa.digitellinc.com/p/s/fdahfsa-special-session-patient-reported-outcomes-challenges-and-opportunities-389
https://hfsa.digitellinc.com/p/s/cardiac-transplantation-in-2017-where-do-we-stand-392
https://hfsa.digitellinc.com/p/s/cardiac-rehabilitation-and-exercise-training-in-patients-with-heart-failure-395
https://hfsa.digitellinc.com/p/s/cgmp-drugs-in-heart-failure-new-developments-398
https://hfsa.digitellinc.com/p/s/lvad-the-beginning-401
https://hfsa.digitellinc.com/p/s/pulmonary-comorbidities-of-hf-copd-and-sleep-apnea-404
https://hfsa.digitellinc.com/p/s/cardiac-amyloid-moving-from-uniformly-fatal-to-chronic-disease-407
https://hfsa.digitellinc.com/p/s/precision-medicine-in-hf-410
https://hfsa.digitellinc.com/p/s/case-discussion-clinical-conundrums-413
https://hfsa.digitellinc.com/p/s/addressing-social-determinants-of-health-416
https://hfsa.digitellinc.com/p/s/cvct-joint-session-what-makes-a-perfect-clinical-trial-419
https://hfsa.digitellinc.com/p/s/jnc-young-investigators-award-clinicalintegrative-422
https://hfsa.digitellinc.com/p/s/jnc-young-investigators-award-basic-science-425
https://hfsa.digitellinc.com/p/s/nursing-investigator-award-428
https://hfsa.digitellinc.com/p/s/big-trials-of-the-past-year-431
https://hfsa.digitellinc.com/p/s/the-right-ventricle-in-hf-434
https://hfsa.digitellinc.com/p/s/from-cancer-biology-to-cardiovascular-pathophysiology-437
https://hfsa.digitellinc.com/p/s/heart-failure-and-women-gender-trumps-selection-440
https://hfsa.digitellinc.com/p/s/social-media-and-hf-443
https://hfsa.digitellinc.com/p/s/the-road-less-traveled-palliative-care-in-hf-446
https://hfsa.digitellinc.com/p/s/what-hf-providers-need-to-know-about-pah-449
https://hfsa.digitellinc.com/p/s/cardiogenic-shock-the-evolution-of-patient-and-device-selection-for-acute-circulatory-support-452
https://hfsa.digitellinc.com/p/s/rapid-fire-abstracts-ii-455
https://hfsa.digitellinc.com/p/s/hfref-therapy-in-2017-and-beyond-sacubitril-ivabradine-patriomer-and-more-458
https://hfsa.digitellinc.com/p/s/genetics-of-cardiomyopathies-461
https://hfsa.digitellinc.com/p/s/redefining-pulmonary-vascular-disease-using-oimcs-the-nih-nhlbi-pvdomics-study-464
https://hfsa.digitellinc.com/p/s/lvad-new-life-different-life-467
https://hfsa.digitellinc.com/p/s/great-debates-in-hf-clinical-trials-470
https://hfsa.digitellinc.com/p/s/best-papers-of-the-year-473
https://hfsa.digitellinc.com/p/s/adult-congenital-heart-disease-and-heart-failure-476
https://hfsa.digitellinc.com/p/s/you-are-what-you-eat-body-composition-and-nutrition-in-heart-failure-479
https://hfsa.digitellinc.com/p/s/aging-hearts-controversies-and-opportunities-for-the-treatment-of-heart-failure-among-older-adults-482
https://hfsa.digitellinc.com/p/s/late-breaking-clinical-trials-485
https://hfsa.digitellinc.com/p/s/developing-heart-failure-syndromes-what-do-we-know-about-hfrecef-488
https://hfsa.digitellinc.com/p/s/controversies-in-cancer-and-cardiovascular-disease-491
https://hfsa.digitellinc.com/p/s/hf-care-in-1987-2017-2047-how-it-was-how-it-is-and-how-it-will-be-494
https://hfsa.digitellinc.com/p/s/peripartum-cardiomyopathy-towards-a-new-understanding-of-mechanisms-outcomes-and-management-497
https://hfsa.digitellinc.com/p/s/whats-new-with-arnis-500
https://hfsa.digitellinc.com/p/s/hyde-park-503
https://hfsa.digitellinc.com/p/s/tweeting-the-experts-a-free-forum-for-the-hardest-questions-506
https://hfsa.digitellinc.com/p/s/caregiver-commitment-the-role-of-the-caregiver-in-patients-with-heart-failure-509
https://hfsa.digitellinc.com/p/s/how-to-develop-and-accomplish-research-a-symposium-for-early-career-professionals-512
https://hfsa.digitellinc.com/p/s/echo-made-simple-for-the-multidisciplinary-team-515
https://hfsa.digitellinc.com/p/s/cardiopulmonary-exercise-testing-how-who-and-what-does-it-mean-518
https://hfsa.digitellinc.com/p/s/discussing-the-impact-of-hyperkalemia-on-management-strategies-for-patients-with-heart-failure-a-town-hall-forum-524
https://hfsa.digitellinc.com/p/s/applying-clinical-advances-in-hf-management-to-optimize-patient-outcomes-527
https://hfsa.digitellinc.com/p/s/satellite-1-541
https://hfsa.digitellinc.com/packages/40/view
https://hfsa.digitellinc.com/packages/46/view
https://hfsa.digitellinc.com/p/cf/2017-comprehensive-heart-failure-review-course-and-update-561
https://hfsa.digitellinc.com/packages/51/view
https://hfsa.digitellinc.com/packages/57/view
https://hfsa.digitellinc.com/p/s/industry-expert-theater-579
https://hfsa.digitellinc.com/p/s/models-and-mechanisms-of-hfref-and-hfpef-585
https://hfsa.digitellinc.com/p/s/new-guidelines-update-590
https://hfsa.digitellinc.com/p/s/arnis-and-ivabradine-595
https://hfsa.digitellinc.com/p/s/emerging-therapies-for-chronic-hf-600
https://hfsa.digitellinc.com/p/s/hfpef-natural-history-and-contemporary-management-605
https://hfsa.digitellinc.com/p/s/case-based-discussion-610
https://hfsa.digitellinc.com/p/s/natural-history-and-patient-assessment-615
https://hfsa.digitellinc.com/p/s/vasodilators-and-inotropes-whats-new-and-what-works-620
https://hfsa.digitellinc.com/p/s/acute-hf-congestion-cardiorenal-syndrome-and-diuretic-resistance-625
https://hfsa.digitellinc.com/p/s/diuretics-in-hospitalized-patients-current-controversies-and-emerging-therapies-630
https://hfsa.digitellinc.com/p/s/patient-assessment-and-classification-635
https://hfsa.digitellinc.com/p/s/treating-pah-in-the-contemporary-era-640
https://hfsa.digitellinc.com/p/s/pulmonary-hypertension-and-left-hf-645
https://hfsa.digitellinc.com/p/s/right-hf-650
https://hfsa.digitellinc.com/p/s/case-based-discussion-655
https://hfsa.digitellinc.com/p/s/assessment-of-patient-with-new-onset-hf-660
https://hfsa.digitellinc.com/p/s/practical-application-of-risk-prediction-models-665
https://hfsa.digitellinc.com/p/s/sleep-disordered-breathing-670
https://hfsa.digitellinc.com/p/s/biomarker-2017-update-whats-hot-whats-not-675
https://hfsa.digitellinc.com/p/s/invasive-and-non-invasive-hemodynamic-devices-680
https://hfsa.digitellinc.com/p/s/remote-monitoring-smart-phones-to-telehealth-685
https://hfsa.digitellinc.com/p/s/clinical-variability-within-intermacs-profile-i-695
https://hfsa.digitellinc.com/p/s/hemodynamics-of-cardiogenic-shock-and-devices-700
https://hfsa.digitellinc.com/p/s/percutaneous-devices-and-ecmo-705
https://hfsa.digitellinc.com/p/s/q-and-a-710
https://hfsa.digitellinc.com/p/s/tricks-of-the-trade-challenges-of-raas-inhibition-715
https://hfsa.digitellinc.com/p/s/advanced-hemodynamic-modeling-720
https://hfsa.digitellinc.com/p/s/defining-advanced-hf-730
https://hfsa.digitellinc.com/p/s/heart-transplant-patient-selection-735
https://hfsa.digitellinc.com/p/s/heart-transplant-clinical-outcomes-and-management-740
https://hfsa.digitellinc.com/p/s/lvad-patient-selection-and-clinical-outcomes-745
https://hfsa.digitellinc.com/p/s/lvad-adverse-events-and-patient-management-750
https://hfsa.digitellinc.com/p/s/managing-drug-interactions-755
https://hfsa.digitellinc.com/p/s/q-and-a-760
https://hfsa.digitellinc.com/p/s/arrhythmia-management-antiarrhythmic-drugs-and-vt-ablation-770
https://hfsa.digitellinc.com/p/s/impact-of-afib-on-hf-775
https://hfsa.digitellinc.com/p/s/systemic-anticoagulation-from-vka-to-noac-780
https://hfsa.digitellinc.com/p/s/prevention-of-sudden-cardiac-death-wearables-and-implantables-785
https://hfsa.digitellinc.com/p/s/cardiac-resynchronization-therapy-recent-advances-790
https://hfsa.digitellinc.com/p/s/q-and-a-795
https://hfsa.digitellinc.com/p/s/how-to-set-up-a-hf-clinic-and-diastolic-hf-program-800
https://hfsa.digitellinc.com/p/s/how-to-setup-a-remote-monitoring-program-805
https://hfsa.digitellinc.com/p/s/having-the-discussion-how-to-make-the-conversation-easier-810
https://hfsa.digitellinc.com/p/s/practical-use-of-biomarkers-in-the-clinical-setting-815
https://hfsa.digitellinc.com/p/s/transplant-vad-case-review-820
https://hfsa.digitellinc.com/p/s/reducing-30-day-readmissions-825
https://hfsa.digitellinc.com/p/s/transitioning-patients-out-of-the-hospital-830
https://hfsa.digitellinc.com/p/s/strategies-for-keeping-patients-out-of-the-hospital-835
https://hfsa.digitellinc.com/p/s/they-are-not-ready-for-palliative-care-really-then-when-840
https://hfsa.digitellinc.com/p/s/case-based-discussion-845
https://hfsa.digitellinc.com/p/s/hypertrophic-cardiomyopathies-and-screening-for-sudden-cardiac-death-850
https://hfsa.digitellinc.com/p/s/cardiac-amyloidosis-855
https://hfsa.digitellinc.com/p/s/pregnancy-and-peripartum-cardiomyopathy-860
https://hfsa.digitellinc.com/p/s/inflammatory-cardiomyopathies-and-myocarditis-865
https://hfsa.digitellinc.com/p/s/metabolic-challenges-obesity-diabetes-anemia-870
https://hfsa.digitellinc.com/p/s/fireside-chat-with-patient-875
https://hfsa.digitellinc.com/p/s/q-and-a-880
https://hfsa.digitellinc.com/p/s/case-based-discussion-894
https://hfsa.digitellinc.com/p/s/reds-lung-fluid-management-experience-shared-by-leading-hf-programs-976
https://hfsa.digitellinc.com/packages/76/view
https://hfsa.digitellinc.com/packages/106/view
https://hfsa.digitellinc.com/packages/116/view
https://hfsa.digitellinc.com/p/s/heart-failure-activity-and-diet-1095
https://hfsa.digitellinc.com/packages/133/view
https://hfsa.digitellinc.com/packages/152/view
https://hfsa.digitellinc.com/packages/164/view
https://hfsa.digitellinc.com/packages/170/view
https://hfsa.digitellinc.com/packages/176/view
https://hfsa.digitellinc.com/packages/182/view
https://hfsa.digitellinc.com/packages/194/view
https://hfsa.digitellinc.com/packages/200/view
https://hfsa.digitellinc.com/packages/206/view
https://hfsa.digitellinc.com/packages/212/view
https://hfsa.digitellinc.com/packages/218/view
https://hfsa.digitellinc.com/packages/224/view
https://hfsa.digitellinc.com/packages/230/view
https://hfsa.digitellinc.com/packages/236/view
https://hfsa.digitellinc.com/packages/242/view
https://hfsa.digitellinc.com/packages/248/view
https://hfsa.digitellinc.com/packages/254/view
https://hfsa.digitellinc.com/packages/260/view
https://hfsa.digitellinc.com/packages/266/view
https://hfsa.digitellinc.com/packages/272/view
https://hfsa.digitellinc.com/p/s/heart-failure-medications-and-challenges-of-multiple-medications-1338
https://hfsa.digitellinc.com/p/s/track-your-heart-health-for-free-using-hfsas-online-tools-heart-failure-health-storylines-1351
https://hfsa.digitellinc.com/p/cf/2018-hf-board-review-course-1358
https://hfsa.digitellinc.com/p/s/heart-failure-epidemiology-and-risk-factors-and-clinical-assessment-diagnosis-and-comorbidities-1369
https://hfsa.digitellinc.com/p/s/heart-failure-clinical-trials-a-patient-centered-tutorial-1402
https://hfsa.digitellinc.com/p/s/welcome-and-introduction-1423
https://hfsa.digitellinc.com/p/s/live-abim-style-question-session-60-min-1429
https://hfsa.digitellinc.com/p/s/pathophysiology-i-cellular-and-energetic-considerations-1435
https://hfsa.digitellinc.com/p/s/hemodynamics-in-hf-i-1447
https://hfsa.digitellinc.com/p/s/hemodynamics-in-hf-ii-1453
https://hfsa.digitellinc.com/p/s/cardiomyopathies-i-ischemic-and-valvular-1459
https://hfsa.digitellinc.com/p/s/cardiomyopathies-ii-nonischemic-and-per-partum-1465
https://hfsa.digitellinc.com/p/s/cardiomyopathies-iii-hcm-amyloid-and-infiltrative-1471
https://hfsa.digitellinc.com/p/s/cardiomyopathies-iv-arvc-and-inherited-1477
https://hfsa.digitellinc.com/p/s/cardio-oncology-1483
https://hfsa.digitellinc.com/p/s/ambulatory-hemodynamic-monitoring-remote-patient-monitoring-1489
https://hfsa.digitellinc.com/p/s/pulmonary-hypertension-1495
https://hfsa.digitellinc.com/p/s/q-and-a-questions-from-the-audience-1501
https://hfsa.digitellinc.com/p/s/live-abim-style-question-session-30-min-1507
https://hfsa.digitellinc.com/p/s/advanced-heart-failure-defining-the-phenotype-and-patient-selection-1513
https://hfsa.digitellinc.com/p/s/immunology-the-basics-pra-sensitization-crossmatch-1519
https://hfsa.digitellinc.com/p/s/rejection-cellular-and-antibody-mediated-1525
https://hfsa.digitellinc.com/p/s/managing-immunosuppression-and-drugs-1531
https://hfsa.digitellinc.com/p/s/heart-transplant-clinical-outcomes-and-complications-1537
https://hfsa.digitellinc.com/p/s/mcs-cardiogenic-shock-and-temporary-support-devices-1543
https://hfsa.digitellinc.com/p/s/mcs-ii-durable-mcs-selection-and-outcomes-1549
https://hfsa.digitellinc.com/p/s/mcs-iii-adverse-events-and-patient-management-1555
https://hfsa.digitellinc.com/p/s/adult-congenital-heart-disease-for-the-hf-specialist-1561
https://hfsa.digitellinc.com/p/s/hf-and-biomarkers-1567
https://hfsa.digitellinc.com/p/s/pericarditis-and-myocarditis-1573
https://hfsa.digitellinc.com/p/s/hfpef-epidemiology-co-morbidities-and-phenomapping-1579
https://hfsa.digitellinc.com/p/s/hfpef-assessment-treatment-and-outcomes-1585
https://hfsa.digitellinc.com/p/s/management-of-arrhythmias-in-heart-failure-1591
https://hfsa.digitellinc.com/p/s/device-therapy-in-heart-failure-1597
https://hfsa.digitellinc.com/p/s/acute-decompensated-heart-failure-i-1609
https://hfsa.digitellinc.com/p/s/acute-decompensated-heart-failure-ii-1615
https://hfsa.digitellinc.com/p/s/drug-therapy-for-chronic-heart-failure-i-1621
https://hfsa.digitellinc.com/p/s/drug-therapy-for-chronic-heart-failure-ii-1627
https://hfsa.digitellinc.com/p/s/assessment-of-functional-capacity-in-hfcpet-1633
https://hfsa.digitellinc.com/p/s/clinico-pathological-correlates-1639
https://hfsa.digitellinc.com/p/s/q-and-a2-1646
https://hfsa.digitellinc.com/p/s/q-and-a3-1658
https://hfsa.digitellinc.com/packages/331/view
https://hfsa.digitellinc.com/packages/337/view
https://hfsa.digitellinc.com/p/cf/hfsa-22nd-annual-scientific-meeting-1689
https://hfsa.digitellinc.com/p/s/tackling-hfpef-from-phenomics-to-novel-therapeutics-1695
https://hfsa.digitellinc.com/p/s/biomarkers-with-more-muscle-moving-beyond-serum-creatinine-to-define-cardiorenal-syndrome-in-hf-1701
https://hfsa.digitellinc.com/p/s/saem-1707
https://hfsa.digitellinc.com/p/s/advancements-and-dilemmas-in-cardio-oncology-1713
https://hfsa.digitellinc.com/p/s/aha-an-imperative-for-public-health-hf-prevention-1719
https://hfsa.digitellinc.com/p/s/a-tale-of-two-ph-due-to-left-heart-disease-and-the-right-ventricle-1725
https://hfsa.digitellinc.com/p/s/aahfn-stop-collaborate-and-listen-innovative-and-effective-team-based-care-1731
https://hfsa.digitellinc.com/p/s/excellence-in-translational-science-cardiac-myosin-new-directions-in-cardiomyopathy-and-hf-1737
https://hfsa.digitellinc.com/p/s/vad-101-an-update-in-mechanical-circulatory-support-1743
https://hfsa.digitellinc.com/p/s/mechanical-circulatory-devices-contemporary-long-term-management-1749
https://hfsa.digitellinc.com/p/s/future-of-healthcare-delivery-in-the-us-1755
https://hfsa.digitellinc.com/p/s/cardiac-amyloidosis-often-misdiagnosed-and-undertreated-1761
https://hfsa.digitellinc.com/p/s/advanced-hf-and-heart-transplantation-for-genetic-cardiomyopathy-1767
https://hfsa.digitellinc.com/p/s/cardiogenic-shock-teams-time-for-a-paradigm-shift-1773
https://hfsa.digitellinc.com/p/s/international-variations-in-hf-therapy-data-guidelines-economics-or-habit-1779
https://hfsa.digitellinc.com/p/s/patient-preferences-1785
https://hfsa.digitellinc.com/p/s/glucose-lowering-therapies-and-hf-a-cardiologists-guide-1791
https://hfsa.digitellinc.com/p/s/advances-in-acquired-cardiomyopathies-myocarditis-sarcoid-and-peripartum-1797
https://hfsa.digitellinc.com/p/s/remote-monitoring-for-hf-1803
https://hfsa.digitellinc.com/p/s/an-integrated-approach-to-understanding-physiologic-subphenotypes-and-their-impact-on-functional-capacity-and-outcomes-in-hfpef-1809
https://hfsa.digitellinc.com/p/s/fifty-years-of-heart-transplantation-a-celebration-and-call-for-action-1815
https://hfsa.digitellinc.com/p/s/government-healthcare-programs-in-hf-1821
https://hfsa.digitellinc.com/p/s/resolving-diagnostic-dilemmas-with-imaging-1827
https://hfsa.digitellinc.com/p/s/cardiac-regeneration-and-cell-therapy-1833
https://hfsa.digitellinc.com/p/s/changing-the-perspective-on-cardiac-amyloidosis-from-missed-and-undiagnosed-to-common-and-treatable-1839
https://hfsa.digitellinc.com/p/s/late-breaking-insights-from-trials-and-novel-investigations-1845
https://hfsa.digitellinc.com/p/s/cutting-edge-of-vad-technology-1851
https://hfsa.digitellinc.com/p/s/help-or-harm-common-controversies-in-the-management-of-hf-1857
https://hfsa.digitellinc.com/p/s/current-approaches-to-geriatrics-and-frailty-in-heart-failure-1863
https://hfsa.digitellinc.com/p/s/the-latest-discoveries-in-peripartum-cardiomyopathy-1869
https://hfsa.digitellinc.com/p/s/clinical-conundrums-case-discussion-1875
https://hfsa.digitellinc.com/p/s/myocardial-recovery-state-of-the-art-1881
https://hfsa.digitellinc.com/p/s/jnc-young-investigators-award-clinicalintegrative-1887
https://hfsa.digitellinc.com/p/s/jnc-young-investigators-award-basic-science-1893
https://hfsa.digitellinc.com/p/s/nursing-investigator-award-1899
https://hfsa.digitellinc.com/p/s/goals-of-care-conversations-in-hf-1905
https://hfsa.digitellinc.com/p/s/how-to-in-research-a-practical-guide-for-early-career-clinicians-1911
https://hfsa.digitellinc.com/p/s/hospital-to-home-how-to-bridge-the-great-divide-1917
https://hfsa.digitellinc.com/p/s/pulmonary-hypertension-1923
https://hfsa.digitellinc.com/p/s/rapid-fire-abstracts-1929
https://hfsa.digitellinc.com/p/s/3-day-readmissions-cant-live-with-them-can-patients-live-without-them-1935
https://hfsa.digitellinc.com/p/s/controversies-in-the-management-of-acute-hf-1941
https://hfsa.digitellinc.com/p/s/immunomodulation-in-hf-1947
https://hfsa.digitellinc.com/p/s/mechanistic-insights-into-hfpef-pathways-for-future-success-1953
https://hfsa.digitellinc.com/p/s/when-athena-needs-a-vad-sex-and-advanced-hf-therapy-1959
https://hfsa.digitellinc.com/p/s/debate-1965
https://hfsa.digitellinc.com/p/s/improving-outcomes-for-failing-congenital-patients-1971
https://hfsa.digitellinc.com/p/s/complex-decision-making-in-hf-1977
https://hfsa.digitellinc.com/p/s/career-development-seminar-1983
https://hfsa.digitellinc.com/p/s/hf-and-hyperkalemia-applying-evidence-based-medicine-for-improved-patient-outcomes-1989
https://hfsa.digitellinc.com/p/s/late-breaking-clinical-trials-1995
https://hfsa.digitellinc.com/p/s/novel-approaches-to-expand-heart-transplantation-2001
https://hfsa.digitellinc.com/p/s/tricks-from-the-hf-toolbox-optimizing-pharmacologic-therapies-2007
https://hfsa.digitellinc.com/p/s/hf-in-the-22nd-century-what-can-we-expect-2013
https://hfsa.digitellinc.com/p/s/voiding-the-gap-optimizing-diuretic-strategies-with-something-old-something-new-something-borrowed-and-something-blue-2019
https://hfsa.digitellinc.com/p/s/contemporary-update-on-pulmonary-hypertension-diagnostic-controversies-and-management-dilemmas-2025
https://hfsa.digitellinc.com/p/s/hyde-park-2031
https://hfsa.digitellinc.com/p/s/fat-frailty-supplements-and-the-microbiome-the-need-to-know-about-nutrition-in-heart-failure-2037
https://hfsa.digitellinc.com/p/s/tweet-the-experts-2043
https://hfsa.digitellinc.com/packages/346/view
https://hfsa.digitellinc.com/packages/358/view
https://hfsa.digitellinc.com/packages/365/view
https://hfsa.digitellinc.com/packages/376/view
https://hfsa.digitellinc.com/p/cf/2019-heart-failure-awareness-week-2090
https://hfsa.digitellinc.com/p/s/heart-failure-medications-and-challenges-of-multiple-medications-2099
https://hfsa.digitellinc.com/p/s/managing-heart-failure-and-diabetes-2117
https://hfsa.digitellinc.com/p/s/heart-failure-diagnostic-testing-and-advanced-therapies-2144
https://hfsa.digitellinc.com/p/cf/hfsa-23rd-annual-scientific-meeting-2163
https://hfsa.digitellinc.com/p/s/excellence-in-translational-science-2171
https://hfsa.digitellinc.com/p/s/mitral-regurgitation-in-heart-failure-2019-challenges-and-opportunities-2181
https://hfsa.digitellinc.com/p/s/cardiovascular-metabolic-and-renal-outcomes-in-multi-morbid-heart-failure-patients-with-type-2-diabetes-2191
https://hfsa.digitellinc.com/p/s/improving-outcomes-in-your-hf-patients-with-evidence-based-treatment-of-hyperkalemia-2201
https://hfsa.digitellinc.com/p/s/independence-from-heart-failure-awareness-empathy-and-activism-2209
https://hfsa.digitellinc.com/p/s/ten-simple-tips-how-to-prevent-hf-2218
https://hfsa.digitellinc.com/p/s/great-debates-and-current-controversies-across-the-atlantic-2227
https://hfsa.digitellinc.com/p/s/acute-cardiogenic-shock-to-recovery-stemi-myocarditis-and-acute-insults-2234
https://hfsa.digitellinc.com/p/s/prognosis-and-treatments-for-ambulatory-advanced-hf-2242
https://hfsa.digitellinc.com/p/s/general-cardiology-vs-community-and-academic-hf-lets-learn-from-each-other-2251
https://hfsa.digitellinc.com/p/s/ten-simple-tips-management-of-complexities-in-cardiogenic-shock-2257
https://hfsa.digitellinc.com/p/s/fda-special-session-focusing-on-patient-in-clinical-research-and-drug-development-2263
https://hfsa.digitellinc.com/p/s/change-is-inevitable-impact-of-nursing-and-allied-health-amongst-the-medical-circulatory-support-world-2269
https://hfsa.digitellinc.com/p/s/challenges-in-managing-adult-congenital-heart-disease-ph-rv-failure-arrhythmia-2278
https://hfsa.digitellinc.com/p/s/rapid-fire-abstracts-for-original-investigations-2287
https://hfsa.digitellinc.com/p/s/symptoms-are-the-tip-of-the-iceberg-navigating-management-of-congestion-in-heart-failure-2294
https://hfsa.digitellinc.com/p/s/team-based-approach-to-combined-medical-and-surgical-management-of-advanced-heart-failure-optimal-use-and-impact-of-mechanical-circulatory-support-2302
https://hfsa.digitellinc.com/p/s/ten-simple-tips-identifying-the-ever-elusive-volume-overload-in-the-clinic-2308
https://hfsa.digitellinc.com/p/s/2019-update-on-clinical-trials-for-emerging-hf-drugs-and-device-therapies-2314
https://hfsa.digitellinc.com/p/s/defining-rv-failure-pathophysiology-and-clinical-perspectives-2323
https://hfsa.digitellinc.com/p/s/jnc-investigator-award-basic-science-and-clinical-2331
https://hfsa.digitellinc.com/p/s/nursing-investigator-award-research-and-clinical-2337
https://hfsa.digitellinc.com/p/s/ten-simple-tips-how-to-best-implement-technologies-to-assist-in-hf-care-and-reduce-readmissions-2346
https://hfsa.digitellinc.com/p/s/hf-in-end-stage-kidney-disease-a-multidisciplinary-approach-to-an-underestimated-problem-2352
https://hfsa.digitellinc.com/p/s/contemporary-dilemmas-in-lvad-therapy-2361
https://hfsa.digitellinc.com/p/s/systemic-pathway-dysregulation-in-hfpef-how-mechanisms-enlighten-clinical-approaches-2366
https://hfsa.digitellinc.com/p/s/fundamental-skills-for-ahftc-training-2367
https://hfsa.digitellinc.com/p/s/2018-2019-top-ten-trials-news-and-publication-in-hf-2373
https://hfsa.digitellinc.com/p/s/systems-of-care-in-cardiogenic-shock-2377
https://hfsa.digitellinc.com/p/s/payer-mandates-for-formal-shared-decision-making-how-do-i-meet-coverage-decision-mandates-2384
https://hfsa.digitellinc.com/p/s/lessons-learned-100-plus-years-from-hf-nurses-2393
https://hfsa.digitellinc.com/p/s/translational-omics-in-heart-failure-finally-getting-clinical-2403
https://hfsa.digitellinc.com/p/s/clinical-conundrums-pharmacotherapy-for-hfref-case-based-debates-2413
https://hfsa.digitellinc.com/p/s/international-session-global-challenges-and-best-practices-in-acute-hf-2418
https://hfsa.digitellinc.com/p/s/how-to-diagnose-and-manage-inflammatory-cardiomyopathies-myocarditis-foundation-2428
https://hfsa.digitellinc.com/p/s/how-to-engage-patient-caregiver-dyads-in-managing-hf-2437
https://hfsa.digitellinc.com/p/s/diet-nutrition-and-cardiac-function-from-beside-to-bench-and-back-again-2443
https://hfsa.digitellinc.com/p/s/reducing-cardiovascular-and-renal-risk-with-sglt2-inhibitors-exploring-evidence-2451
https://hfsa.digitellinc.com/p/s/brave-new-world-of-attr-cardiac-amyloidosis-avoiding-pitfalls-in-diagnosis-and-treatment-2457
https://hfsa.digitellinc.com/p/s/ten-simple-tips-cardiac-amyloidosis-no-longer-an-academic-exercise-now-a-treatable-pandemic-2463
https://hfsa.digitellinc.com/p/s/controversies-in-acute-cardio-renal-syndrome-discussion-and-debates-on-fluid-wars-2473
https://hfsa.digitellinc.com/p/s/clinical-conundrums-managing-afib-and-device-therapies-in-hf-case-based-debates-2478
https://hfsa.digitellinc.com/p/s/advocacy-committee-the-multidimensional-challenge-of-drug-pricing-and-preapprovals-2486
https://hfsa.digitellinc.com/p/s/how-to-manage-cardiovascular-complications-during-pregnancy-2492
https://hfsa.digitellinc.com/p/s/late-breaking-clinical-trials-2496
https://hfsa.digitellinc.com/p/s/ten-simple-tips-management-of-patients-with-diabetes-and-hf-2501
https://hfsa.digitellinc.com/p/s/functional-mitral-regurgitation-an-update-on-treatment-strategies-2508
https://hfsa.digitellinc.com/p/s/the-spectrum-of-care-for-patients-with-genetic-cardiomyopathies-2518
https://hfsa.digitellinc.com/p/s/barriers-to-implementation-of-new-therapies-2524
https://hfsa.digitellinc.com/p/s/late-breaking-clinical-trials-and-insights-with-angiotensin-receptor-neprilysn-inhibitors-2529
https://hfsa.digitellinc.com/p/s/ten-simple-tips-how-to-best-treat-volume-overload-in-acute-hf-2534
https://hfsa.digitellinc.com/p/s/understanding-the-heart-brain-connection-new-insights-in-cognitive-impairment-and-sleep-disordered-breathing-2543
https://hfsa.digitellinc.com/p/s/the-new-heart-transplantation-allocation-2549
https://hfsa.digitellinc.com/p/s/new-insights-in-cardio-oncology-2558
https://hfsa.digitellinc.com/p/s/pharmacist-driven-transition-of-care-and-optimization-clinics-2567
https://hfsa.digitellinc.com/p/s/hf-awareness-in-african-americans-2573
https://hfsa.digitellinc.com/p/s/hyde-park-2577
https://hfsa.digitellinc.com/p/s/ten-simple-tips-managing-patients-across-the-spectrum-of-pulmonary-hypertension-2578
https://hfsa.digitellinc.com/p/s/addressing-the-recovered-ejection-fraction-is-it-still-heart-failure-2587
https://hfsa.digitellinc.com/p/s/the-psychosocial-assessment-of-the-advanced-hf-patient-2592
https://hfsa.digitellinc.com/p/s/learning-health-systems-real-world-evidence-and-hf-hype-or-reality-2598
https://hfsa.digitellinc.com/p/s/acute-and-chronic-hf-2746
https://hfsa.digitellinc.com/p/s/models-and-mechanisms-of-hfref-and-hfpef-2751
https://hfsa.digitellinc.com/p/s/hf-pathway-translating-guidelines-into-clinical-practice-2756
https://hfsa.digitellinc.com/p/s/transcatheter-mitral-valve-repair-and-replacement-2761
https://hfsa.digitellinc.com/p/s/diabetes-and-heart-failure-2766
https://hfsa.digitellinc.com/p/s/emerging-therapies-new-indications-and-drugs-in-the-pipeline-2771
https://hfsa.digitellinc.com/p/s/hfpef-therapeutic-options-2776
https://hfsa.digitellinc.com/p/s/acute-hf-natural-history-and-patient-assessment-2781
https://hfsa.digitellinc.com/p/s/inotropes-whats-new-2786
https://hfsa.digitellinc.com/p/s/acute-hf-congestion-cardiorenal-and-diuretic-resistance-2791
https://hfsa.digitellinc.com/p/s/case-based-discussion-hf-across-lifespan-acute-and-chronic-2796
https://hfsa.digitellinc.com/p/s/pulmonary-hypertension-and-rv-failure-2816
https://hfsa.digitellinc.com/p/s/pulmonary-hypertension-i-diagnosis-and-management-2821
https://hfsa.digitellinc.com/p/s/pulmonary-hypertension-ii-pharmacotherapy-2826
https://hfsa.digitellinc.com/p/s/who-ii-ph-and-right-failure-2831
https://hfsa.digitellinc.com/p/s/case-based-discussion-2836
https://hfsa.digitellinc.com/p/s/assessment-of-patient-with-new-onset-hf-2851
https://hfsa.digitellinc.com/p/s/cardiopulmonary-exercise-stress-testing-cpet-2861
https://hfsa.digitellinc.com/p/s/how-to-set-up-a-hf-clinic-2866
https://hfsa.digitellinc.com/p/s/advances-in-patient-monitoring-2871
https://hfsa.digitellinc.com/p/s/biomarker-2019-update-whats-hot-whats-not-2876
https://hfsa.digitellinc.com/p/s/invasive-and-non-invasive-hemodynamic-devices-2881
https://hfsa.digitellinc.com/p/s/remote-monitoring-smart-phones-to-telehealth-2886
https://hfsa.digitellinc.com/p/s/sleep-disordered-breathing-2891
https://hfsa.digitellinc.com/p/s/q-and-a-2896
https://hfsa.digitellinc.com/p/s/cardiogenic-shock-pathophysiology-hemodynamics-and-outcomes-2906
https://hfsa.digitellinc.com/p/s/percutaneous-devices-and-ecmo-2911
https://hfsa.digitellinc.com/p/s/cardiac-amyloidosis-2916
https://hfsa.digitellinc.com/p/s/tricks-of-the-trade-challenges-of-raas-inhibition-2921
https://hfsa.digitellinc.com/p/s/troubleshooting-lvad-alarms-2926
https://hfsa.digitellinc.com/p/s/lvad-patient-selection-and-clinical-outcomes-2936
https://hfsa.digitellinc.com/p/s/lvad-adverse-events-and-patient-management-2941
https://hfsa.digitellinc.com/p/s/heart-transplant-clinical-outcomes-and-management-2946
https://hfsa.digitellinc.com/p/s/managing-drug-interactions-2951
https://hfsa.digitellinc.com/p/s/q-and-a-2956
https://hfsa.digitellinc.com/p/s/special-session-patient-preferences-2961
https://hfsa.digitellinc.com/p/s/hf-and-arrhythmia-management-2966
https://hfsa.digitellinc.com/p/s/impact-of-afib-on-hf-2971
https://hfsa.digitellinc.com/p/s/ep-device-therapy-of-hf-crt-his-bundle-pacing-and-ccm-2976
https://hfsa.digitellinc.com/p/s/arrhythmia-management-antiarrhythmic-drugs-and-vt-ablation-2981
https://hfsa.digitellinc.com/p/s/prevention-of-sudden-cardiac-death-wearables-and-implantables-2986
https://hfsa.digitellinc.com/p/s/how-to-setup-a-remote-monitoring-program-2991
https://hfsa.digitellinc.com/p/s/having-the-discussion-how-to-make-the-conversation-easier-2996
https://hfsa.digitellinc.com/p/s/clinical-conundrums-case-review-3001
https://hfsa.digitellinc.com/p/s/special-populations-3006
https://hfsa.digitellinc.com/p/s/defining-advance-hf-3011
https://hfsa.digitellinc.com/p/s/inflammatory-cardiomyopathies-myocarditis-and-sarcoidosis-3016
https://hfsa.digitellinc.com/p/s/metabolic-challenges-obesity-and-anemia-3021
https://hfsa.digitellinc.com/p/s/hf-and-pregnancy-3026
https://hfsa.digitellinc.com/p/s/hypertrophic-cardiomyopathies-and-screening-for-sudden-cardiac-death-3031
https://hfsa.digitellinc.com/p/s/transitional-and-palliative-care-3036
https://hfsa.digitellinc.com/p/s/cardio-oncology-3041
https://hfsa.digitellinc.com/p/s/transitional-care-planning-and-strategies-for-keeping-people-out-of-the-hospital-3046
https://hfsa.digitellinc.com/p/s/palliative-care-and-hospice-3051
https://hfsa.digitellinc.com/p/s/q-and-a-3056
https://hfsa.digitellinc.com/p/s/advanced-heart-failure-when-patients-should-seek-help-3068
https://hfsa.digitellinc.com/p/s/emotional-wellness-in-heart-failure-and-the-caregiver-challenge-3083
https://hfsa.digitellinc.com/p/s/physical-activity-and-diet-in-heart-failure-3108
https://hfsa.digitellinc.com/p/cf/2020-hfsa-board-certification-review-course-virtual-live-stream-3116
https://hfsa.digitellinc.com/p/s/heart-failure-epidemiology-and-risk-factors-3123
https://hfsa.digitellinc.com/p/s/pathophysiology-i-cellular-and-energetic-considerations-3129
https://hfsa.digitellinc.com/p/s/pathophysiology-ii-hemodynamic-structural-and-neurohormonal-considerations-3136
https://hfsa.digitellinc.com/p/s/diagnosis-and-clinical-assessment-3143
https://hfsa.digitellinc.com/p/s/device-therapy-in-heart-failure-3149
https://hfsa.digitellinc.com/p/s/cardio-oncology-for-the-hf-boards-3156
https://hfsa.digitellinc.com/p/s/clinico-pathologic-correlates-in-heart-failure-images-for-the-heart-failure-boards-3162
https://hfsa.digitellinc.com/p/s/welcome-and-hfsa-introduction-day-1-3168
https://hfsa.digitellinc.com/p/s/advanced-heart-failure-defining-the-phenotype-and-patient-selection-for-advanced-therapies-3178
https://hfsa.digitellinc.com/p/s/immunology-the-basics-pra-sensitization-crossmatch-3183
https://hfsa.digitellinc.com/p/s/rejection-cellular-and-antibody-mediated-3188
https://hfsa.digitellinc.com/p/s/managing-immunosuppression-and-drugs-3193
https://hfsa.digitellinc.com/p/s/heart-transplant-clinical-outcomes-and-complications-3198
https://hfsa.digitellinc.com/p/s/welcome-and-introductions-day-3-3203
https://hfsa.digitellinc.com/p/s/hemodynamics-in-hf-i-3213
https://hfsa.digitellinc.com/p/s/hemodynamics-in-hf-ii-3218
https://hfsa.digitellinc.com/p/s/drug-therapy-for-chronic-hf-i-focus-on-established-therapies-acearbbeta-blockermradigoxinhydralazine-plus-nitrates-3223
https://hfsa.digitellinc.com/p/s/drug-therapy-for-chronic-hf-ii-focus-on-newer-therapies-sacubitrilvalsartan-ivabradine-sglt2-inhibitors-3228
https://hfsa.digitellinc.com/p/s/hfpef-epidemiology-risk-factors-diagnosis-management-for-the-boards-3233
https://hfsa.digitellinc.com/p/s/management-of-the-hospitalized-hf-patient-3238
https://hfsa.digitellinc.com/p/s/management-of-common-arrhythmias-in-hf-including-af-3243
https://hfsa.digitellinc.com/p/s/management-of-comorbidities-in-heart-failure-3248
https://hfsa.digitellinc.com/p/s/adult-congenital-heart-disease-for-the-hf-specialist-3263
https://hfsa.digitellinc.com/p/s/specific-etiologies-of-hf-ii-inherited-hf-syndromes-including-hcm-arvc-and-lvnc-3268
https://hfsa.digitellinc.com/p/s/specific-etiologies-of-hf-iii-infiltrative-disorders-and-restrictive-cardiomyopathy-amyloidosis-sarcoidosis-hemochromatosis-fabry-3278
https://hfsa.digitellinc.com/p/s/welcome-and-introductions-day-2-3288
https://hfsa.digitellinc.com/p/s/cardiogenic-shock-management-3298
https://hfsa.digitellinc.com/p/s/mcs-i-durable-mcs-devices-and-outcomes-3303
https://hfsa.digitellinc.com/p/s/mcs-ii-temporary-support-devices-and-ecmo-for-the-boards-3308
https://hfsa.digitellinc.com/p/s/mcs-iii-mcs-complications-and-patient-management-3313
https://hfsa.digitellinc.com/p/s/mcs-iv-troubleshooting-with-harvi-3318
https://hfsa.digitellinc.com/p/s/assessment-of-functional-capacity-including-cardiopulmonary-exercise-testing-3328
https://hfsa.digitellinc.com/p/s/specific-etiologies-of-hf-i-common-etiologies-cad-etoh-peripartum-myocarditis-3333
https://hfsa.digitellinc.com/p/s/issues-in-chronic-hf-disease-management-biomarkers-remote-monitoring-lifestyle-interventions-3338
https://hfsa.digitellinc.com/p/s/management-of-valvular-heart-disease-in-heart-failure-including-functional-mr-low-gradient-as-tricuspid-regurgitation-3343
https://hfsa.digitellinc.com/p/s/pulmonary-hypertension-3348
https://hfsa.digitellinc.com/p/s/heart-failure-fundamentals-3382
https://hfsa.digitellinc.com/p/s/q-and-a-panel-i-3409
https://hfsa.digitellinc.com/p/s/q-and-a-panel-ii-3416
https://hfsa.digitellinc.com/p/cf/health-disparities-in-heart-failure-livestream-panel-3423
https://hfsa.digitellinc.com/p/s/health-disparities-in-heart-failure-livestream-panel-3433
https://hfsa.digitellinc.com/p/cf/942020-chair-q-and-a-3448
https://hfsa.digitellinc.com/p/s/faculty-office-hours-q-and-a-panel-3466
https://hfsa.digitellinc.com/p/cf/2020-patient-day-3483
https://hfsa.digitellinc.com/p/s/welcome-introductions-and-highlights-from-the-2020-annual-scientific-3491
https://hfsa.digitellinc.com/p/s/updates-from-clinical-trials-expanded-uses-for-new-therapies-3497
https://hfsa.digitellinc.com/p/s/q-and-a-faculty-3524
https://hfsa.digitellinc.com/p/s/living-with-heart-failure-3533
https://hfsa.digitellinc.com/p/s/closing-remarks-and-breakout-session-information-3636
https://hfsa.digitellinc.com/p/cf/2021-virtual-board-certification-review-course-3649
https://hfsa.digitellinc.com/p/s/welcome-and-hfsa-introductions-3668
https://hfsa.digitellinc.com/p/s/session-i-cardiac-transplantation-3676
https://hfsa.digitellinc.com/p/s/advanced-heart-failure-defining-the-phenotype-and-patient-selection-for-advanced-therapies-3684
https://hfsa.digitellinc.com/p/s/immunology-the-basics-pra-sensitization-crossmatch-3692
https://hfsa.digitellinc.com/p/s/rejection-cellular-and-antibody-mediated-3700
https://hfsa.digitellinc.com/p/s/managing-immunosuppression-and-drugs-3708
https://hfsa.digitellinc.com/p/s/heart-transplant-clinical-outcomes-and-complications-3724
https://hfsa.digitellinc.com/p/s/q-and-a-panel-i-3732
https://hfsa.digitellinc.com/p/s/welcome-and-introductions-3740
https://hfsa.digitellinc.com/p/s/session-ii-key-issues-in-hf-management-part-i-3748
https://hfsa.digitellinc.com/p/s/hemodynamics-in-hf-i-3756
https://hfsa.digitellinc.com/p/s/hemodynamics-in-hf-ii-3764
https://hfsa.digitellinc.com/p/s/drug-therapy-for-chronic-hf-i-focus-on-established-therapies-acearbbeta-blockermradigoxinhydralazine-plus-nitrates-3772
https://hfsa.digitellinc.com/p/s/drug-therapy-for-chronic-hf-ii-focus-on-newer-therapies-sacubitrilvalsartan-ivabradine-sglt2-inhibitors-3780
https://hfsa.digitellinc.com/p/s/break-3788
https://hfsa.digitellinc.com/p/s/session-ii-key-issues-in-hf-management-part-ii-3796
https://hfsa.digitellinc.com/p/s/hfpef-epidemiology-risk-factors-diagnosis-management-for-the-boards-3804
https://hfsa.digitellinc.com/p/s/pulmonary-hypertension-3812
https://hfsa.digitellinc.com/p/s/management-of-common-arrhythmias-i-atrial-fib-and-flutter-3820
https://hfsa.digitellinc.com/p/s/management-of-common-arrhythmias-in-hf-ii-3828
https://hfsa.digitellinc.com/p/s/device-therapy-in-heart-failure-i-sudden-death-prevention-3836
https://hfsa.digitellinc.com/p/s/device-therapy-in-heart-failure-ii-crt-3844
https://hfsa.digitellinc.com/p/s/break-3852
https://hfsa.digitellinc.com/p/s/session-ii-key-issues-in-hf-management-part-iii-3860
https://hfsa.digitellinc.com/p/s/management-of-the-hospitalized-hf-patient-3868
https://hfsa.digitellinc.com/p/s/cardio-renal-failure-interactions-in-heart-failure-3876
https://hfsa.digitellinc.com/p/s/session-iii-specific-heart-failure-syndromes-3884
https://hfsa.digitellinc.com/p/s/specific-etiologies-of-hf-i-common-etiologies-cad-etoh-peripartum-myocarditis-3892
https://hfsa.digitellinc.com/p/s/specific-etiologies-of-hf-ii-inherited-hf-syndromes-including-hcm-arvc-and-lvnc-3900
https://hfsa.digitellinc.com/p/s/specific-etiologies-of-hf-iii-infiltrative-disorders-and-restrictive-cardiomyopathy-amyloidosis-sarcoidosis-hemochromatosis-fabry-3908
https://hfsa.digitellinc.com/p/s/q-and-a-panel-ii-3916
https://hfsa.digitellinc.com/p/s/welcome-and-introductions-3924
https://hfsa.digitellinc.com/p/s/session-iv-shockmcs-3932
https://hfsa.digitellinc.com/p/s/cardiogenic-shock-management-3940
https://hfsa.digitellinc.com/p/s/mcs-i-durable-mcs-devices-and-outcomes-3948
https://hfsa.digitellinc.com/p/s/mcs-ii-temporary-support-devices-and-ecmo-for-the-boards-3956
https://hfsa.digitellinc.com/p/s/mcs-iii-mcs-complications-and-patient-management-3964
https://hfsa.digitellinc.com/p/s/mcs-iv-interactive-shock-and-device-management-note-live-session-3972
https://hfsa.digitellinc.com/p/s/break-3980
https://hfsa.digitellinc.com/p/s/session-v-special-topics-in-hf-3988
https://hfsa.digitellinc.com/p/s/assessment-of-functional-capacity-including-cardiopulmonary-exercise-testing-3996
https://hfsa.digitellinc.com/p/s/adult-congenital-heart-disease-for-the-hf-specialist-4004
https://hfsa.digitellinc.com/p/s/issues-in-chronic-hf-disease-management-biomarkers-remote-monitoring-lifestyle-interventions-4012
https://hfsa.digitellinc.com/p/s/management-of-valvular-heart-disease-in-heart-failure-including-functional-mr-low-gradient-as-tricuspid-regurgitation-4020
https://hfsa.digitellinc.com/p/s/management-of-comorbidities-in-heart-failure-diabetes-sleep-disorders-iron-deficiencyanemia-copd-4028
https://hfsa.digitellinc.com/p/s/q-and-a-panel-iii-4036
https://hfsa.digitellinc.com/p/cf/2021-patient-education-webinar-series-4038
https://hfsa.digitellinc.com/p/s/hfsa-heart-failure-seminar-guidelines-directed-medical-therapy-gdmt-4048
https://hfsa.digitellinc.com/p/s/ondemand-webinars-heart-failure-fundamentals-4050
https://hfsa.digitellinc.com/p/s/heart-failure-epidemiology-and-risk-factors-4055
https://hfsa.digitellinc.com/p/s/pathophysiology-i-cellular-and-energetic-considerations-4060
https://hfsa.digitellinc.com/p/s/pathophysiology-ii-hemodynamic-structural-and-neurohormonal-considerations-4065
https://hfsa.digitellinc.com/p/s/diagnosis-and-clinical-assessment-4070
https://hfsa.digitellinc.com/p/s/cardio-oncology-for-the-hf-boards-4075
https://hfsa.digitellinc.com/p/s/clinico-pathologic-correlates-in-heart-failure-images-for-the-heart-failure-boards-4080
https://hfsa.digitellinc.com/p/s/statistics-for-the-hf-board-4085
https://hfsa.digitellinc.com/p/s/faculty-office-hours-4094
https://hfsa.digitellinc.com/p/cf/2022-virtual-patient-and-caregiver-day-4099
https://hfsa.digitellinc.com/p/s/welcome-opening-remarks-and-introductions-4104
https://hfsa.digitellinc.com/p/s/newly-diagnosed-resources-and-support-for-patients-and-caregivers-4109
https://hfsa.digitellinc.com/p/s/next-steps-exploring-medication-devices-and-advanced-therapies-4114
https://hfsa.digitellinc.com/p/s/exploring-clinical-research-advocating-for-yourself-or-others-4119
https://hfsa.digitellinc.com/p/s/sound-body-sound-mind-managing-diet-exercise-and-mental-health-4124
https://hfsa.digitellinc.com/p/s/exercise-demonstration-break-4129
https://hfsa.digitellinc.com/p/s/heart-healthy-cooking-demonstration-4134
https://hfsa.digitellinc.com/p/s/closing-remarks-4139
https://hfsa.digitellinc.com/p/s/visit-sponsor-and-participating-patient-and-provider-group-resource-pages-4144
https://hfsa.digitellinc.com/p/cf/2022-patient-education-webinar-series-4145
https://hfsa.digitellinc.com/p/cf/2022-board-certification-review-4146
https://hfsa.digitellinc.com/p/s/welcome-and-hfsa-introduction-4147
https://hfsa.digitellinc.com/p/s/session-i-cardiac-transplantation-part-i-4148
https://hfsa.digitellinc.com/p/s/advanced-heart-failure-defining-the-phenotype-and-patient-selection-for-advanced-therapies-4149
https://hfsa.digitellinc.com/p/s/live-q-and-a-advanced-heart-failure-defining-the-phenotype-and-patient-selection-for-advanced-therapies-4150
https://hfsa.digitellinc.com/p/s/immunology-the-basics-pra-sensitization-crossmatch-4151
https://hfsa.digitellinc.com/p/s/rejection-cellular-and-antibody-mediated-4152
https://hfsa.digitellinc.com/p/s/live-q-and-a-immunology-the-basics-pra-sensitization-crossmatch-and-rejection-cellular-and-antibody-mediated-4153
https://hfsa.digitellinc.com/p/s/break-4154
https://hfsa.digitellinc.com/p/s/session-i-cardiac-transplantation-part-ii-4155
https://hfsa.digitellinc.com/p/s/managing-immunosuppression-and-drugs-4156
https://hfsa.digitellinc.com/p/s/heart-transplant-clinical-outcomes-and-complications-4157
https://hfsa.digitellinc.com/p/s/live-q-and-a-managing-immunosuppression-and-drugs-and-heart-transplant-clinical-outcomes-and-complications-4158
https://hfsa.digitellinc.com/p/s/q-and-a-faculty-panel-day-1-4159
https://hfsa.digitellinc.com/p/s/welcome-day-2-4160
https://hfsa.digitellinc.com/p/s/session-ii-key-issues-in-hf-management-part-i-4161
https://hfsa.digitellinc.com/p/s/hemodynamics-in-hf-ii-4162
https://hfsa.digitellinc.com/p/s/live-q-and-a-hemodynamics-in-hf-ii-4163
https://hfsa.digitellinc.com/p/s/optimal-medical-therapy-for-heart-failure-with-reduced-ejection-fraction-4164
https://hfsa.digitellinc.com/p/s/application-and-implementation-of-drug-therapies-for-heart-failure-with-reduced-ejection-fraction-new-4165
https://hfsa.digitellinc.com/p/s/live-q-and-a-optimal-medical-therapy-for-heart-failure-with-reduced-ejection-fraction-application-and-implementation-of-drug-therapies-for-heart-failure-with-reduced-ejection-fraction-new-4166
https://hfsa.digitellinc.com/p/s/hfpef-epidemiology-risk-factors-diagnosis-management-for-the-boards-4167
https://hfsa.digitellinc.com/p/s/live-q-and-a-hfpef-epidemiology-risk-factors-diagnosis-management-for-the-boards-4168
https://hfsa.digitellinc.com/p/s/break-4169
https://hfsa.digitellinc.com/p/s/session-ii-key-issues-in-hf-management-part-ii-4170
https://hfsa.digitellinc.com/p/s/management-of-comorbidities-in-heart-failure-iron-deficiencyanemia-4171
https://hfsa.digitellinc.com/p/s/live-q-and-a-4172
https://hfsa.digitellinc.com/p/s/pulmonary-hypertension-therapy-4173
https://hfsa.digitellinc.com/p/s/live-q-and-a-4174
https://hfsa.digitellinc.com/p/s/management-of-common-arrhythmias-i-atrial-fib-and-flutter-4175
https://hfsa.digitellinc.com/p/s/management-of-common-arrhythmias-ii-4176
https://hfsa.digitellinc.com/p/s/live-q-and-a-4177
https://hfsa.digitellinc.com/p/s/device-therapy-in-heart-failure-i-sudden-death-prevention-4178
https://hfsa.digitellinc.com/p/s/device-therapy-in-heart-failure-ii-crt-4179
https://hfsa.digitellinc.com/p/s/live-q-and-a-4180
https://hfsa.digitellinc.com/p/s/break-4181
https://hfsa.digitellinc.com/p/s/session-ii-key-issues-in-hf-management-part-iii-4182
https://hfsa.digitellinc.com/p/s/management-of-the-hospitalized-hf-patient-4183
https://hfsa.digitellinc.com/p/s/live-q-and-a-4184
https://hfsa.digitellinc.com/p/s/cardio-renal-failure-interactions-in-heart-failure-4185
https://hfsa.digitellinc.com/p/s/live-q-and-a-4186
https://hfsa.digitellinc.com/p/s/session-iii-specific-heart-failure-syndromes-4187
https://hfsa.digitellinc.com/p/s/specific-etiologies-of-hf-i-common-etiologies-cad-etoh-peripartum-myocarditis-4188
https://hfsa.digitellinc.com/p/s/live-q-and-a-4189
https://hfsa.digitellinc.com/p/s/specific-etiologies-of-hf-ii-inherited-hf-syndromes-including-hcm-arvc-and-lvnc-4190
https://hfsa.digitellinc.com/p/s/live-q-and-a-4191
https://hfsa.digitellinc.com/p/s/specific-etiologies-of-hf-iii-infiltrative-disorders-and-restrictive-cardiomyopathy-amyloidosis-sarcoidosis-hemochromatosis-fabry-4192
https://hfsa.digitellinc.com/p/s/live-q-and-a-4193
https://hfsa.digitellinc.com/p/s/q-and-a-faculty-panel-day-2-4194
https://hfsa.digitellinc.com/p/s/welcome-day-3-4195
https://hfsa.digitellinc.com/p/s/session-iv-shockmcs-4196
https://hfsa.digitellinc.com/p/s/cardiogenic-shock-management-4197
https://hfsa.digitellinc.com/p/s/live-q-and-a-4198
https://hfsa.digitellinc.com/p/s/mcs-i-durable-mcs-devices-and-outcomes-4199
https://hfsa.digitellinc.com/p/s/live-q-and-a-4200
https://hfsa.digitellinc.com/p/s/mcs-ii-temporary-support-devices-and-ecmo-for-the-boards-4201
https://hfsa.digitellinc.com/p/s/mcs-iii-mcs-complications-and-patient-management-4202
https://hfsa.digitellinc.com/p/s/live-q-and-a-4203
https://hfsa.digitellinc.com/p/s/mcs-iv-interactive-shock-and-device-management-case-1-4204
https://hfsa.digitellinc.com/p/s/mcs-iv-interactive-shock-and-device-management-case-2-4205
https://hfsa.digitellinc.com/p/s/mcs-iv-interactive-shock-and-device-management-case-3-4206
https://hfsa.digitellinc.com/p/s/break-4207
https://hfsa.digitellinc.com/p/s/session-v-special-topics-in-hf-4208
https://hfsa.digitellinc.com/p/s/assessment-of-functional-capacity-including-cardiopulmonary-exercise-testing-4209
https://hfsa.digitellinc.com/p/s/live-q-and-a-4210
https://hfsa.digitellinc.com/p/s/healthcare-disparities-in-hf-4211
https://hfsa.digitellinc.com/p/s/live-q-and-a-4212
https://hfsa.digitellinc.com/p/s/issues-in-chronic-hf-disease-management-biomarkers-remote-monitoring-lifestyle-interventions-4213
https://hfsa.digitellinc.com/p/s/live-q-and-a-4214
https://hfsa.digitellinc.com/p/s/management-of-left-sided-valvular-heart-disease-in-heart-failure-including-functional-mr-low-gradient-as-4215
https://hfsa.digitellinc.com/p/s/live-q-and-a-4216
https://hfsa.digitellinc.com/p/s/adult-congenital-heart-disease-for-the-hf-specialist-4217
https://hfsa.digitellinc.com/p/s/live-q-and-a-4218
https://hfsa.digitellinc.com/p/s/q-and-a-faculty-panel-day-3-4219
https://hfsa.digitellinc.com/p/s/heart-failure-fundamentals-ondemand-webinar-4221
https://hfsa.digitellinc.com/p/s/heart-failure-epidemiology-and-risk-factors-4222
https://hfsa.digitellinc.com/p/s/pathophysiology-i-cellular-and-energetic-considerations-4223
https://hfsa.digitellinc.com/p/s/pathophysiology-ii-hemodynamic-structural-and-neurohormonal-considerations-4224
https://hfsa.digitellinc.com/p/s/diagnosis-and-clinical-assessment-4225
https://hfsa.digitellinc.com/p/s/cardio-oncology-for-the-hf-boards-4226
https://hfsa.digitellinc.com/p/s/clinico-pathologic-correlates-in-heart-failure-images-for-the-heart-failure-boards-4227
https://hfsa.digitellinc.com/p/s/statistics-for-the-hf-board-4228
https://hfsa.digitellinc.com/p/s/hemodynamics-in-hf-i-4229
https://hfsa.digitellinc.com/p/s/pulmonary-hypertension-classification-and-initial-evaluation-4230
https://hfsa.digitellinc.com/p/s/diabetes-and-copd-4231
https://hfsa.digitellinc.com/p/s/rv-failure-and-tr-management-4232
https://hfsa.digitellinc.com/p/s/faculty-office-hours-4233
https://hfsa.digitellinc.com/p/s/management-of-comorbidities-in-heart-failure-sleep-disorder-4234
https://hfsa.digitellinc.com/p/cf/2024-patient-education-webinar-series-4236
https://hfsa.digitellinc.com/p/s/cardiac-amyloidosis-the-heart-of-the-matter-4239